Website News and Research

RSS

New website launched by Vita Advisors for the health care industry

Vita Advisors LLC is pleased to announce the introduction of its website: http://vitaadvisors.com. The VITA website home page features three areas of content designed to provide its business constituents in the health care industry with a quick and valuable daily resource for current issues relevant to their business.

9 Sep 2009

Health care reform without curbing medical costs will make Americans suffer: Concord Coalition Leaders

Concord Coalition Co-Chairs Warren B. Rudman and Bob Kerrey today called on President Obama to push for concrete measures, including a federal health care budget, to curb runaway medical costs.

9 Sep 2009

Inactivation of ClpX gene may help treat anthrax poisoning

Scientists from the University of California (San Diego) have identified a gene in B. anthracis that not only contributes to the severity of the anthrax disease but also makes it more difficult for a patient's immune system to fight the infection.

8 Sep 2009

Microline PENTAX launches rebranded website and new company logo

Microline PENTAX, Inc., a leading manufacturer of reposable instruments for minimally invasive surgery, announced today that it has completed the change of its corporate name to Microline Surgical, Inc. The company will also issue a new logo and launch a rebranded website.

8 Sep 2009

Impact Fusion International completes geographic market test of Intact Digest

Impact Fusion International announced today it has successfully completed a limited geographic market test for Intact Digest with several retail vitamin stores re-ordering on a monthly basis.

8 Sep 2009

Capsule expands marketing program

After extensive planning, strategizing, and consulting, Capsule, the leading provider of medical device connectivity, has announced that they are expanding their marketing program to include social media. From Twitter, to Capsule's very own Facebook fan page, Capsule is ready to engage and gain new insights in order to better serve the clinical and HIT community.

8 Sep 2009

Lupus Foundation of America takes steps to address shortage of participants for clinical trial

It has been more than 50 years since the U.S. Food and Drug Administration (FDA) last approved a new medicine specifically for lupus – when Dwight D. Eisenhower was president. Existing treatments have been "borrowed" from other disorders and the risk/benefit ratio of these treatments is far from optimal. However, hope is on the horizon.

8 Sep 2009

3Sbio announces date for shareholders' annual general meeting

3SBio Inc.("3SBio" or "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that the annual general meeting of shareholders of 3SBio Inc. will be held on October 12, 2009 at 10:00 a.m., Shenyang time, at No.3 A1, Road 10, Shenyang Economy & Technology Development Zone, Shenyang 110027, People's Republic of China. The shareholder record date is September 12, 2009.

7 Sep 2009

£560,000 grant awarded to set up UK International Health Links Centre

Liverpool School of Tropical Medicine (LSTM) and Liverpool Associates in Tropical Health (LATH) have received a £560,000 grant from the UK's Department for International Development (DFID) to set up and deliver a UK International Health Links Centre (IHLC).

7 Sep 2009

New tool for easy assessment of pesticide effects on water bodies

Leipzig: The long-term effects of pesticides on living organisms in rivers and on water quality can now be assessed more easily. Researchers from the Helmholtz Centre for Environmental Research (UFZ) have developed a tool that can estimate the harmful effect of pesticides, such as those flushed into rivers and streams from agricultural land, within minutes.

5 Sep 2009

Averion files information statement with SEC for going private transaction

Averion International Corporation (OTC BB: AVRO), today announced that it has filed an information statement with the Securities and Exchange Commission (SEC) regarding its plan to go private.

5 Sep 2009

Securities class action lawsuit filed against Repros Therapeutics

Feazell & Tighe, L.L.P. announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of Texas on behalf of all persons or entities who purchased or otherwise acquired the common stock of Repros Therapeutics Inc. (“Repros” or the “Company”) (Nasdaq:RPRX), between July 1, 2009 and August 3, 2009, inclusive (the “Class Period”).

5 Sep 2009

Clinical trial of Cerebroprotein Hydrolysate for Injection completes

Hard to Treat Diseases (the "Company") announced today, that its China based subsidiary Mellow Hope, has just finished (August 2009) the clinical trial of Cerebroprotein Hydrolysate for Injection (Brand name: NUTRIPROTEIN) in India.

5 Sep 2009

Researchers identify new molecular switch that produces cancer cells

A team of Syracuse University researchers discovered a second molecular switch within the Mixed Lineage Leukemia protein complex that they believe could be exploited to prevent the overproduction of abnormal cells that are found in several types of cancer, including leukemia.

4 Sep 2009

TV awareness campaign to dispel the negative stigma regarding mental illness

The National Alliance on Mental Illness (NAMI) Michigan is launching a television awareness campaign this holiday weekend designed to dispel the negative stigma associated with mental illness.

4 Sep 2009

Healthland and PMI form partnership to provide EIS solutions to small community hospitals

Healthland, America's market leader of healthcare information solutions for small community and critical access hospitals, announced today it has partnered with the Performance Management Institute (PMI), to deliver an innovative solution to small community hospitals. PMI works with numerous state networks and hospital systems to provide a platform for monitoring and performance.

4 Sep 2009

Results of Phase 2 rheumatoid arthritis clinical trial announced

Array BioPharma Inc. (Nasdaq: ARRY) announced its preliminary analysis of results from a study examining ARRY-162, a small molecule MEK inhibitor, in a 12-week Phase 2 clinical trial with 201 patients.

4 Sep 2009

Educating teenagers could lower accident risk, says NRSF

As millions of teens head back to school, many will be driving to and from classes every day.

3 Sep 2009

Updated Blue Spoon Consulting briefing note available for web download

Blue Spoon Consulting Group, LLC, today updated its briefing note examining the degrading trends in pharmaceutical marketing, and what can be done about it. Available for download through the Blue Spoon Consulting website (www.bluespoonconsulting.com), ‘Pharmaceutical Promotion At Its Productivity Frontier’ is currently the only piece of strategic writing that looks at a total context of change shaping how pharmaceutical companies market and measure performance.

3 Sep 2009

Boston Scientific reports two-year data from SYNTAX clinical trial

Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that its corporate partner, Boston Scientific (NYSE: BSX), has reported two-year data from its SYNTAX clinical trial comparing percutaneous coronary intervention (PCI) using the Taxus(R) Express(R) Paclitaxel-Eluting Coronary Stent System to coronary artery bypass graft (CABG) surgery.

3 Sep 2009